Tandem Diabetes Care (NSDQ:TNDM) announced today that it won an expanded pediatric indication from the FDA for its t:slim X2 insulin pump.
The t:slim X2 with Control-IQ technology won FDA clearance for controlling Type 1 diabetes in December, which was followed by a commercial launch in the U.S. the next month. Tandem touts t:slim X2 with Control-IQ as the first and only system cleared to deliver automatic correction boluses in addition to adjusting insulin.
Get the full story at our sister site, Drug Delivery Business News.